Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions
Date
2010-10-26
Authors
Koido, Shigeo
Homma, Sadamu
Hara, Eiichi
Namiki, Yoshihisa
Takahara, Akitaka
Komita, Hideo
Nagasaki, Eijiro
Ito, Masaki
Ohkusa, Toshifumi
Gong, Jianlin
Version
OA Version
Citation
Koido, Shigeo, Sadamu Homma, Eiichi Hara, Yoshihisa Namiki, Akitaka Takahara, Hideo Komita, Eijiro Nagasaki, Masaki Ito, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri. "Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions" Clinical and Developmental Immunology 2010:516768. (2010)
Abstract
The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment.
Description
License
Copyright 2010 Koido et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.